Premier Biotech Expands Point-of-Care Testing Footprint with GH Solutions Buy

Event summary

  • Premier Biotech acquired GH Solutions, a distributor of point-of-care diagnostic testing products, on April 9, 2026.
  • GH Solutions serves government and workplace end markets across the United States.
  • The acquisition adds long-term customers to Premier’s Government and Workplace businesses with significant cross-sell potential.
  • Premier Biotech has completed five acquisitions since partnering with Align Capital Partners in November 2022.

The big picture

The acquisition of GH Solutions aligns with Premier Biotech's strategy to expand its leadership position in the drug and alcohol testing industry. This move comes amid broader trends of consolidation in the healthcare diagnostics sector, as companies seek to enhance their service offerings and customer reach. With Align Capital Partners' support, Premier Biotech aims to accelerate growth through strategic acquisitions and collaborations.

What we're watching

Integration Challenges
How Premier Biotech will integrate GH Solutions' customer base and service offerings into its existing operations.
Cross-Sell Potential
The pace at which Premier Biotech can leverage GH Solutions' customer network to drive additional revenue through its broader product portfolio.
Future Acquisitions
Whether Premier Biotech will continue its aggressive acquisition strategy to further consolidate the point-of-care testing market.

Related topics

Acquisition